WARSAW, Ind., June 27,
2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and
SIX: ZBH) ("Zimmer Biomet") today announced the early termination
of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as amended, for its offer to purchase all
outstanding shares of common stock of LDR Holding Corporation
(NASDAQ: LDRH) ("LDR").
As previously announced, Zimmer Biomet, through its indirect
wholly owned subsidiary, LH Merger Sub, Inc., commenced an offer on
June 14, 2016 to purchase all of the
outstanding shares of common stock of LDR for $37.00 per share, net to the seller in
cash.
The early termination of the waiting period satisfies one of the
conditions to the offer, which will expire at 12:00 midnight,
New York City time, on
July 13, 2016 (one minute after
11:59 p.m., New York City time, on July 12, 2016), unless the offer is extended as
described in the Offer to Purchase filed by Zimmer Biomet with the
Securities and Exchange Commission on June
14, 2016. The completion of the offer is subject to the
tender of a majority of the outstanding shares of common stock of
LDR and other customary closing conditions described in such Offer
to Purchase.
About Zimmer Biomet
Founded in 1927 and headquartered
in Warsaw, Indiana, Zimmer Biomet
is a global leader in musculoskeletal healthcare. We design,
manufacture and market orthopaedic reconstructive products; sports
medicine, biologics, extremities and trauma products; spine, bone
healing, craniomaxillofacial and thoracic products; dental
implants; and related surgical products.
We collaborate with healthcare professionals around the globe to
advance the pace of innovation. Our products and solutions help
treat patients suffering from disorders of, or injuries to, bones,
joints or supporting soft tissues. Together with healthcare
professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world
and sell products in more than 100 countries. For more information,
visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter
at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This release may contain forward-looking
statements related to Zimmer Biomet, LDR and the acquisition of LDR
by Zimmer Biomet. All statements other than statements of
historical fact are, or may be deemed to be, forward-looking
statements. These forward-looking statements are based on the
current expectations and beliefs of management and are subject to
certain known and unknown risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Risks and uncertainties include, among
other things, risks related to the satisfaction of the conditions
to closing the acquisition in the anticipated timeframe or at all,
including uncertainties as to how many of LDR's stockholders will
tender their shares of LDR common stock in the tender offer and the
possibility that the acquisition does not close; risks related to
the ability to realize the anticipated benefits of the acquisition,
including the possibility that the expected benefits from the
proposed acquisition will not be realized or will not be realized
within the expected time period; the risk that the businesses will
not be integrated successfully; disruption from the transaction
making it more difficult to maintain business and operational
relationships; negative effects of the announcement or the
consummation of the proposed acquisition on the market price of
Zimmer Biomet common stock and on Zimmer Biomet's operating
results; significant transaction costs; unknown liabilities; the
risk of litigation and/or regulatory actions related to the
proposed acquisition; other business effects, including the effects
of industry, market, economic, political or regulatory conditions;
future exchange rates and interest rates; changes in tax and other
laws, regulations and policies; future business combinations or
disposals; the uncertainties inherent in research and development;
and competitive developments. Readers are cautioned not to place
undue reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Zimmer
Biomet undertakes no obligation to update any of these
forward-looking statements as the result of new information or to
reflect events or circumstances after the date of this
release or to reflect actual outcomes. A further description of
risks and uncertainties relating to Zimmer Biomet can be found in
its Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 and in its subsequent Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
(the "SEC") and available at www.sec.gov.
Additional Information
This release is for
informational purposes only and is neither an offer to purchase nor
a solicitation of an offer to sell shares of LDR common stock.
Zimmer Biomet has filed with the SEC a tender offer statement on
Schedule TO, including an offer to purchase, a letter of
transmittal and other related materials, regarding the tender offer
described herein, and LDR has filed with the SEC a
solicitation/recommendation statement on Schedule 14D-9 regarding
such tender offer. LDR's stockholders are strongly advised to read
these tender offer materials, as well as any other documents
relating to the tender offer and the associated transactions that
are filed with the SEC, carefully and in their entirety, as they
may be amended from time to time, because they contain important
information about the tender offer that LDR's stockholders should
consider prior to making any decisions with respect to the tender
offer. Stockholders of LDR may obtain a free copy of these
documents at the website maintained by the SEC at www.sec.gov, or
by directing a request to Innisfree M&A Incorporated, the
Information Agent for the tender offer, at (888) 750-5834.
Logo - http://photos.prnewswire.com/prnh/20150624/225371LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/zimmer-biomet-announces-early-termination-of-hsr-waiting-period-300290408.html
SOURCE Zimmer Biomet Holdings, Inc.